Published in Immunol Cell Biol on February 01, 1999
NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood (2009) 1.29
The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol (2007) 1.29
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia (2011) 1.07
Mitochondrial complex I deficiency leads to inflammation and retinal ganglion cell death in the Ndufs4 mouse. Hum Mol Genet (2015) 0.86
Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. Biores Open Access (2012) 0.79
Uterine Natural Killer Cells: Functional Distinctions and Influence on Pregnancy in Humans and Mice. Front Immunol (2017) 0.76
Type 1 Innate Lymphoid Cell Biology: Lessons Learnt from Natural Killer Cells. Front Immunol (2016) 0.76
Clinical Behavior in Metastatic Brain Disease Is Not Influenced by the Immunological Defense Mediated by CD57 NK-Cells. Int J Surg Oncol (2011) 0.76
CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse. Genes Immun (2016) 0.75
The Influenza Virus Protein PB1-F2 Increases Viral Pathogenesis through Neutrophil Recruitment and NK Cells Inhibition. PLoS One (2016) 0.75
Modelling the Innate Immune Response against Avian Influenza Virus in Chicken. PLoS One (2016) 0.75
High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol Immunother (2016) 0.75
Recognition and Regulation of T Cells by NK Cells. Front Immunol (2016) 0.75
CD8αα+MHC Class II+ Cell with the Capacity To Terminate Autoimmune Inflammation Is a Novel Antigen-Presenting NK-like Cell in Rats. J Immunol (2016) 0.75
Blocking the Ccl2-Ccr2 axis using Ccl2 neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol Cancer Ther (2016) 0.75
Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives. Curr Transplant Rep (2017) 0.75
MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis (2017) 0.75
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
NKT cells are phenotypically and functionally diverse. Eur J Immunol (1999) 1.97
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem (1997) 1.88
Role of ceramide in cellular senescence. J Biol Chem (1995) 1.74
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci (2000) 1.58
Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. Proc Natl Acad Sci U S A (1992) 1.55
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med (1999) 1.45
CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol (2007) 1.45
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol (2001) 1.40
Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J Biol Chem (1998) 1.36
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo. J Exp Med (1990) 1.24
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol (2001) 1.19
Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem (1996) 1.17
Immunopurification of functional Asp-ase (natural killer cell granzyme B) using a monoclonal antibody. Biochem Biophys Res Commun (1993) 1.14
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
p53-dependent ceramide response to genotoxic stress. J Clin Invest (1998) 1.11
Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol (2001) 1.07
Exploration of the Common Bile Duct for Stone. Drainage with T-Tube and Cholangiography. Br Med J (1941) 1.07
CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today (1999) 1.07
Evolution in action. Nature (1974) 1.06
Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol (2000) 1.02
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther (2010) 1.00
HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood (2000) 1.00
Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res (1999) 0.99
A role for P-glycoprotein in regulating cell death. Leuk Lymphoma (2000) 0.99
P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ (2002) 0.97
Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ (2004) 0.96
Granule serine proteases are normal nuclear constituents of natural killer cells. J Biol Chem (1994) 0.95
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol (2000) 0.94
Automated single-cell manipulation and sorting by light trapping. Appl Opt (1987) 0.93
Bcl-2 acts upstream of the PARP protease and prevents its activation. Cell Death Differ (1997) 0.92
Perforin-dependent nuclear entry of granzyme B precedes apoptosis, and is not a consequence of nuclear membrane dysfunction. Cell Death Differ (1998) 0.92
Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol (1992) 0.92
The restricted expression of granzyme M in human lymphocytes. J Immunol (2001) 0.91
Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homolog, BHRF1. Cell Death Differ (2000) 0.90
The subunit structure of the aliphatic amidase from Pseudomonas aeruginosa. Eur J Biochem (1973) 0.90
Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther (2010) 0.89
Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol (1998) 0.88
Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. Eur J Immunol (2001) 0.88
Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res (1998) 0.87
Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med (2000) 0.87
The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics (1994) 0.86
m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J Exp Med (1999) 0.85
Killing by cytotoxic T cells and natural killer cells: multiple granule serine proteases as initiators of DNA fragmentation. Immunol Cell Biol (1993) 0.83
Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther (2007) 0.83
Purification and cloning of a novel serine protease, RNK-Tryp-2, from the granules of a rat NK cell leukemia. J Immunol (1994) 0.82
Expression of human perforin in a mouse cytotoxic T lymphocyte cell line: evidence for perturbation of granule-mediated cytotoxicity. J Leukoc Biol (1993) 0.82
T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J Leukoc Biol (2000) 0.81
Role of CD2 in regulation of CD3- LGL function. Eur Cytokine Netw (1991) 0.81
P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins. J Biol Chem (2001) 0.81
Chemoimmunoconjugates for the treatment of cancer. Adv Immunol (1994) 0.80
Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol (1995) 0.80
Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther (2008) 0.80
The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunol Cell Biol (1987) 0.79
Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. J Immunol (1991) 0.79
Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes. Cancer Immunol Immunother (1999) 0.79
Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3. J Leukoc Biol (1996) 0.79
Equivalent death of P-glycoprotein expressing and nonexpressing cells induced by the protein kinase C inhibitor staurosporine. Biochem Biophys Res Commun (2000) 0.78
Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies. J Natl Cancer Inst (1986) 0.78
The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors. J Leukoc Biol (1996) 0.78
The mode of action of methotrexate-monoclonal antibody conjugates. Immunol Cell Biol (1987) 0.77
The gene encoding a human natural killer cell granule serine protease, Met-ase 1, maps to chromosome 19p13.3. Immunogenetics (1994) 0.76
The natural killer cell serine protease gene Lmet1 maps to mouse chromosome 10. Immunogenetics (1995) 0.75
The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab')2 conjugates. Br J Cancer (1987) 0.75
Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. Cancer Res (1987) 0.75
Cloning and expression of the recombinant mouse natural killer cell granzyme Met-ase-1. Immunogenetics (1996) 0.75
cDNA cloning of granzyme J. Immunogenetics (1997) 0.75
The use of anthracycline-antibody complexes for specific antitumor activity. Targeted Diagn Ther (1988) 0.75
Role of monoclonal antibodies in the therapy of solid tumours. Aust N Z J Surg (1988) 0.75
The question begs--what is the role of P-glycoprotein in normal physiology? Drug Resist Updat (1998) 0.75
Preclinical studies with immunoconjugates. Targeted Diagn Ther (1989) 0.75
Potentiation of the in vitro cytotoxicity of chlorambucil by monoclonal antibodies. J Immunol (1986) 0.75
Letter: Lincomycin and the colon. N Y State J Med (1975) 0.75
P-4 and RNKP-7, new granzyme-like serine proteases expressed in activated rat lymphocytes. J Immunol (1997) 0.75
Differential regulation of interleukin-1 gene expression in human CD3- large granular lymphocytes. Cell Immunol (1990) 0.75
The peptide loop consisting of amino acids 139-157 of human granzyme B (fragmentin 2) contains an immunodominant epitope recognized by the mouse. Mol Immunol (1995) 0.75
Payment for medical authors. J R Soc Med (1979) 0.75
Role of the tryptophan residue in the interaction of pancreozymin with its receptor. Biochim Biophys Acta (1980) 0.75
Evidence that an anthracycline-anti-CD8 immunoconjugate, idarubicin-anti-Ly-2.1, prolongs heart allograft survival in mice. Transplantation (1993) 0.75
Redirected cytotoxic effector function. Requirements for expression of chimeric single chain high affinity immunoglobulin e receptors. J Biol Chem (1996) 0.75
Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res (1988) 0.75